Search

everythinglearnresearchcommunity

for

Search:↓

Female mice with disrupted 5α-reductase 1 had significant metabolic issues, including stress response problems, insulin resistance, liver fat buildup, and obesity.

Hormones like estrogen, testosterone, progesterone, and prolactin play complex roles in female sexual function, with testosterone potentially improving sexual desire, arousal, and satisfaction. However, more research is needed to establish safe and effective hormone treatments for female sexual dysfunction.

Younger transgender women have surgery earlier, are mostly attracted to men, and show more preoperative depression that improves after surgery compared to older transgender women.

Inhibiting 5α-reductase during late pregnancy shortens gestation, reduces litter size, and harms memory in rat offspring.

Individuals with male pseudohermaphroditism often do better raised as females with early surgery.

Women have a higher DHT/testosterone ratio than men, possibly due to gut bacteria activity.

Hormone therapy increases the risk of heart-related issues in transgender women and may affect heart health in transgender men.

Androgens affect many aspects of female health, and more research is needed to understand their roles and treatment potential.

The paper suggests that a decrease in estrogen receptor activity may cause sexual dysfunction syndromes and proposes hormonal treatments.

Male tissue has more cell death than female tissue after ischemia, and some neurosteroids only protect female cells.

Men have higher COVID-19 mortality rates than women due to biological and lifestyle factors.

The document concludes that proper diagnosis and individualized treatment are crucial for managing androgenization in women effectively.

Masculinizing hormone therapy increases the risk of hair loss in transgender and gender-diverse patients.

PFAS exposure in adolescence may delay puberty in females.

Transgender and nonbinary individuals experience hair loss, with transmen on testosterone seeing more severe hair loss, while feminizing hormones may stabilize hair loss in transwomen.

Most youth with gender dysphoria received hormones, had minor complications, and showed a decrease in suicide attempts after treatment.

After menopause, some women lose scalp hair and gain facial hair, with patterns suggesting different underlying causes.

Testosterone undecanoate increases lean mass and causes various physical changes in female-to-male transsexuals.

Blocking androgen activity in newborn rats affects body weight and appetite-related hormones differently in males and females.

Finasteride reduces prostate size and DHT in male mastomys but not in females.

Hormonal imbalances can cause skin and hair problems in women, and treatments that block male hormones can help.

Prenatal pesticide exposure may cause earlier breast development in girls.

The document concludes that antiandrogenic drugs like cyproterone acetate and spironolactone are effective but not permanent treatments for skin-related androgenization in women.

Hormonal treatment in transgender women reduces semen quality, but stopping treatment may improve it.

Finasteride helps treat hair loss and prostate issues by blocking a hormone.

The document concludes that cosmetic surgery is still mainly a practice for women and the gender gap in this field is expected to continue.

Including androgens in hormone therapy may lower breast cancer risk.

Men are more likely to have severe COVID-19 cases and fatalities than women due to factors like lifestyle, aging, and biological differences.